Enterprise Value
805.1M
Cash
157.9M
Avg Qtr Burn
-14.49M
Short % of Float
27.23%
Insider Ownership
21.43%
Institutional Own.
64.72%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
YUTREPIA (Treprostinil) (LIQ861) Details Rare diseases, Pulmonary arterial hypertension, Lung disease, Pulmonary hypertension associated with interstitial lung disease | Approved Update | |
YUTREPIA (Treprostinil) (LIQ861) Details Pulmonary arterial hypertension, Lung disease, Pulmonary hypertension associated with interstitial lung disease, Rare diseases Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
L606 Details Pulmonary hypertension associated with interstitial lung disease, Pulmonary arterial hypertension | Phase 3 Data readout | |
LIQ865 Details Post-surgical pain | Failed Discontinued |